Cargando…

Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT

Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance. Previous studies showed that Allicin could inhibit multiple cancer cells including glioblastoma, but the function of Allicin in glioblastoma is still unclear. Our work aimed to investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Henggang, Li, Xu, Zhang, Tiehui, Zhang, Guojun, Chen, Jingnan, Chen, Li, He, Min, Hao, Bilie, Wang, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417398/ https://www.ncbi.nlm.nih.gov/pubmed/32086739 http://dx.doi.org/10.1007/s12017-020-08592-5

Ejemplares similares

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression
por: Gao, Yong-tao, et al.
Publicado: (2016)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide
por: Li, Haisong, et al.
Publicado: (2021)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2
por: Yi, Guo-zhong, et al.
Publicado: (2019)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression
por: Persano, L, et al.
Publicado: (2012)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression
por: Li, Qiang, et al.
Publicado: (2020)

Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of MGMT and BCL-XL
por: Tang, Jun-Hai, et al.
Publicado: (2017)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
por: Nie, Er, et al.
Publicado: (2018)

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
por: Perazzoli, Gloria, et al.
Publicado: (2015)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation
por: Wu, Moli, et al.
Publicado: (2023)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
por: Kurdi, Maher, et al.
Publicado: (2021)

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
por: Ganesa, Sachita, et al.
Publicado: (2022)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_81ld0kbr1jh78i8okdeq0b0u2m